Greenphire unveils a groundbreaking Patient Experience Dataset, establishing the industry’s first repository of global patient-level insights. This dataset provides comprehensive information on average stipends, reimbursements, travel methods and expenses, regulatory compliance guidelines, and more.
Through this dataset, sponsors and CROs gain unparalleled visibility into the patient journey, enabling them to:
• Accurately assess the burden associated with trial participation
• Forecast and budget more effectively
• Predict and enhance enrollment
• Streamline EC & IRB submissions
• Optimize patient experience
Greenphire CEO Jim Murphy highlights the significance of the dataset’s scope by indicating that their dataset spans a diverse range of therapeutic areas, phases, and countries across thousands of studies.
This dataset transforms study planning and budgeting by providing access to:
• Average stipend and reimbursement costs by cost category and percentile
• Tools for layered assumptions, estimations, and scenario analysis
Historically, patient compensation in clinical trials has been inconsistent. However, the DIA’s Patient Reimbursement Consortium, with Greenphire as a key member, is working to optimize reimbursement.
Greenphire continues to innovate, following its acquisition of Clincierge and the launch of this data offering. The company is committed to redefining the future of clinical trials through groundbreaking initiatives, advanced technology, and exceptional service enhancements.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
